Skip to content

Screening of specific intestinal flora and establishment of model in patients with immunotherapy sensitive cholangiocarcinoma and pancreatic tumor

Screening of specific intestinal flora and establishment of model in patients with immunotherapy sensitive cholangiocarcinoma and pancreatic tumor

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300067523
Enrollment
Unknown
Registered
2023-01-10
Start date
2023-02-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary pancreatic tumor

Interventions

Case series:NO

Sponsors

Chinese People's Liberation Army (PLA) General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with advanced pancreatic or cholangiocarcinoma diagnosed for the first time and older than 18 years of age 2. Pre-treatment biopsy pathology showed advanced pancreatic or cholangiocarcinoma 3. Without adjuvant chemoradiotherapy and surgery 4. No history of autoimmune disease or diabetes 5. No antibiotics or therapeutic probiotics have been used in the past 8 weeks 6. No intestinal disease or other systemic diseases 7. No special diet (e.g. vegetarian)

Exclusion criteria

Exclusion criteria: 1. A history of cancer, pancreatitis, acute or chronic intestinal inflammation 2. Patients with chronic diarrhea 3. Women on their period 4. Neurodegenerative diseases such as Alzheimer's and Parkinson's

Design outcomes

Primary

MeasureTime frame
RECIST Standard;

Secondary

MeasureTime frame
Overall survival time;Progression-free survival;Objective response rate;

Countries

China

Contacts

Public ContactRong Liu

Chinese People's Liberation Army (PLA) General Hospital

liurong301@126.com66937591

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026